You are here: Industry Insights > ESKD

News List

EC Grants Orphan Designation to Sparsentan for IgA Nephropathy americanpharmaceuticalreview
February 24, 2021
Travere Therapeutics announced the European Commission (EC) has granted orphan designation to sparsentan for the treatment of IgA nephropathy (IgAN), a rare kidney disorder and a leading cause of end-stage kidney disease (ESKD).
Trials Underway to Study COVID-19 Impact on Dialysis Patients americanpharmaceuticalreview
August 24, 2020
DaVita Clinical Research (DCR), a subsidiary of DaVita Inc., has begun enrollment on two clinical research trials to study how COVID-19 affects people with end stage kidney disease (ESKD) who are currently receiving dialysis.
Major Cardiovascular Diseases May Up Long-Term Risk for ESKD drugs
January 15, 2020
Major incident cardiovascular disease events are associated with an increased risk for end-stage kidney disease (ESKD), with the highest risk for heart failure, according to a study published online January in the Journal of the American Society of Nephro
Rates of Palliative Care Rising for Inpatients With ESKD on Dialysis drugs
August 27, 2019
There was an increase in provision of palliative care for patients hospitalized between 2006 and 2014 with end-stage kidney disease (ESKD) requiring dialysis...
Hospitalizations With Psych Diagnosis Common in ESKD drugs
August 26, 2019
Hospitalizations with psychiatric diagnoses are common in pediatric and adult patients with end-stage kidney disease (ESKD)...
Incidence of End-Stage Kidney Disease Up in Australia drugs
January 02, 2019
For nonindigenous people with type 2 diabetes mellitus (T2DM) in Australia, the age-standardized incidence of end-stage kidney disease (ESKD) increased from 2002 to 2013....